{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:24:54Z","timestamp":1761845094109},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venous thromboembolism (VTE) is a common complication in ambulatory cancer patients receiving chemotherapy. Current clinical guidelines recommend against the use of routine primary thromboprophylaxis in unselected ambulatory cancer patients. The Khorana score is a risk assessment tool derived and prospectively validated for the identification of cancer patients at high risk of thrombotic complications. Recently, 2 randomized, controlled trials have assessed the use of low-dose direct oral Xa inhibitors, apixaban and rivaroxaban, for the prevention of cancer-associated thrombosis in ambulatory patients at intermediate to high risk of VTE (Khorana score \u22652). Taken together, these trials have shown that low-dose direct oral Xa inhibitors reduce the risk of VTE in this patient population without a significant increase in major bleeding. These results should encourage clinicians to consider the use of primary thromboprophylaxis in ambulatory cancer patients at intermediate to high risk of VTE who do not have any apparent risk factors for bleeding. The direct oral Xa inhibitors have also been assessed in the acute management of cancer-associated thrombosis. Current evidence suggests that these drugs are a convenient, effective, and safe option for the management of acute VTE in many cancer patients. Low-molecular weight heparin, however, may continue to be the treatment of choice depending on the presence of bleeding risk factors, the type of cancer, drug-drug interactions, and patient preferences.<\/jats:p>","DOI":"10.1182\/hematology.2019000023","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:11:07Z","timestamp":1575645067000},"page":"158-166","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["What's new in the prevention and treatment of cancer-associated thrombosis?"],"prefix":"10.1182","volume":"2019","author":[{"given":"Miriam","family":"Kimpton","sequence":"first","affiliation":[{"name":"Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2019120610094048800_B1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019120610094048800_B2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"2019120610094048800_B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"2019120610094048800_B4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019120610094048800_B5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb Res"},{"issue":"6","key":"2019120610094048800_B6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"2019120610094048800_B7","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines","volume":"22","author":"Mandal\u00e0","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"2019120610094048800_B8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019120610094048800_B9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2019120610094048800_B10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019120610094048800_B11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.thromres.2012.09.010","article-title":"Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study","volume":"130","author":"Elit","year":"2012","journal-title":"Thromb Res"},{"issue":"2","key":"2019120610094048800_B12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"key":"2019120610094048800_B13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"issue":"6","key":"2019120610094048800_B14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2013.09.026","article-title":"Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study","volume":"132","author":"Lecumberri","year":"2013","journal-title":"Thromb Res"},{"issue":"5","key":"2019120610094048800_B15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019120610094048800_B16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2019120610094048800_B17","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"van Doormaal","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019120610094048800_B18","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2019120610094048800_B19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"issue":"17","key":"2019120610094048800_B20","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019120610094048800_B21","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2019120610094048800_B22","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019120610094048800_B23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.thromres.2015.08.002","article-title":"Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis","volume":"136","author":"Lustig","year":"2015","journal-title":"Thromb Res"},{"issue":"suppl 1","key":"2019120610094048800_B24","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.thromres.2018.01.036","article-title":"Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future","volume":"164","author":"Khorana","year":"2018","journal-title":"Thromb Res"},{"issue":"8","key":"2019120610094048800_B25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2019120610094048800_B26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019120610094048800_B27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2019120610094048800_B28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2019120610094048800_B29","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"2019120610094048800_B30","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/jth.14130","article-title":"Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort","volume":"16","author":"Blix","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019120610094048800_B31","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/annonc\/mdq720","article-title":"Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients","volume":"22","author":"Font","year":"2011","journal-title":"Ann Oncol"},{"issue":"17","key":"2019120610094048800_B32","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","article-title":"Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients","volume":"29","author":"den Exter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019120610094048800_B33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/jth.12325","article-title":"Embolic burden of incidental pulmonary embolism diagnosed on routinely performed contrast-enhanced computed tomography imaging in cancer patients","volume":"11","author":"den Exter","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019120610094048800_B34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jth.13172","article-title":"Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients","volume":"14","author":"van der Hulle","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019120610094048800_B35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1538-7836.2010.04114.x","article-title":"Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning","volume":"9","author":"O\u2019Connell","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019120610094048800_B36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/asheducation-2017.1.121","article-title":"Incidental venous thromboembolism: is anticoagulation indicated?","volume":"2017","author":"Di Nisio","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2019120610094048800_B37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/rth2.12176","article-title":"Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting","volume":"3","author":"Kunapareddy","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"2019120610094048800_B38","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"2019120610094048800_B39","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","article-title":"Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019120610094048800_B40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016;150(4):988]","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"10","key":"2019120610094048800_B41","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol"},{"key":"2019120610094048800_B42","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2019120610094048800_B43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2019120610094048800_B44","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"2019120610094048800_B45","author":"McBane"},{"issue":"5","key":"2019120610094048800_B46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.25.4266","article-title":"Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus","volume":"25","author":"Carrier","year":"2018","journal-title":"Curr Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/158\/1546087\/hem2019000023c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/158\/1546087\/hem2019000023c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T20:54:44Z","timestamp":1612990484000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/158\/422585\/Whats-new-in-the-prevention-and-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000023","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}